Strong Revenue Performance#
Dexcom, a company specializing in continuous glucose monitoring devices, reported impressive first-quarter revenue of $1.19 billion. This figure marks a 15% increase compared to the same period last year and surpasses Wall Street's expectations of $1.18 billion. Additionally, the company achieved adjusted earnings of 56 cents per share, exceeding the anticipated 47 cents per share.
Full-Year Outlook Reaffirmed#
Despite the positive quarterly results, Dexcom's shares fell by 4.3% in after-hours trading. The company reaffirmed its full-year revenue guidance, projecting earnings between $5.16 billion and $5.25 billion. Analysts had estimated a revenue of $5.23 billion for the year.
Product Launches and Innovations#
During the quarter, Dexcom expanded the U.S. launch of its G7 15 Day sensor and introduced new meal-logging features to its Stelo platform. These innovations aim to enhance user experience and provide better management tools for diabetes care.
Sustained Demand for Technology#
Dexcom noted that demand for its continuous glucose monitoring devices remains strong. The technology, which eliminates the need for finger-prick blood tests, has become increasingly popular as awareness of diabetes care grows and insurance coverage improves.